The Role of Dendritic Cell in Cancers and Immune Diseases
Deadline for manuscript submissions: closed (20 January 2023) | Viewed by 10843
Interests: dendritic cells; advanced therapy medicinal products; TIL; quality control test; flow cytometry; potency test; GMP regulation
Special Issues, Collections and Topics in MDPI journals
Dendritic cells (DCs) are the most efficient antigen-presenting cells, and thus play a central role in immunity. Their main function is to process antigen material and present it on the cell surface to the T cells of the immune system. They act as messengers between the innate and the adaptive immune systems. Their ability to generate specific anti-tumor T cells, able to infiltrate the tumor bed and kill the target cells through cytolytic mechanisms (i.e., perforin and granzyme B), has led to the use of dendritic cells loaded with tumor antigens in several clinical studies.
Moreover, the modulation of DCs can lead to defective or dysregulated T-cell-mediated immunity and subsequently decreased resistance to infectious disease, or, conversely, increased incidence of allergies or autoimmune disease. Improved knowledge on the role of the altered distribution and/or incorrect functionality of DCs may lead to an improvement in therapy for these autoimmune diseases.
In this Special Issue, we invite contributions in the form of original research articles, reviews, or shorter perspective articles on all aspects related to dendritic cells and the themes above.
Dr. Massimiliano Petrini
Dr. Laura Ridolfi
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- DCs and tumor immunotherapy
- immune modulation
- mechanisms of action
- clinical trials
- future perspectives for DC-based therapy
- adoptive immunotherapy and DCS
- regulatory aspects for DC generation